Detalles de la búsqueda
1.
2023 Updated MASCC/ESMO Consensus Recommendations: prevention of radiotherapy- and chemoradiotherapy-induced nausea and vomiting.
Support Care Cancer
; 32(1): 26, 2023 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38097904
2.
Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC/ESMO consensus recommendation.
Support Care Cancer
; 32(1): 53, 2023 Dec 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38129530
3.
2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents.
Support Care Cancer
; 32(1): 45, 2023 Dec 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38114821
4.
Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data.
Oncologist
; 26(6): e1073-e1082, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33555084
5.
Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
Cochrane Database Syst Rev
; 11: CD012775, 2021 11 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-34784425
6.
Storage, Utilization, and Disposal of Hematopoietic Stem Cell Products in Patients with Multiple Myeloma.
Biol Blood Marrow Transplant
; 26(9): 1589-1596, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32428735
7.
Immunotherapy in Underrepresented Populations of Patients with Cancer: Do We Have Enough Evidence at Present? A Focus on Patients with Major Viral Infections and Autoimmune Disorders.
Oncologist
; 25(6): e946-e954, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32181960
8.
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type.
BMC Cancer
; 20(1): 918, 2020 Sep 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-32988373
9.
Low-dose peripheral blood stem cell graft after high-dose chemotherapy - an evaluation of hematopoietic reconstitution.
BMC Cancer
; 20(1): 353, 2020 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-32334570
10.
Integration of oncology and palliative care: a Lancet Oncology Commission.
Lancet Oncol
; 19(11): e588-e653, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30344075
11.
Nivolumab maintenance after salvage autologous stem cell transplantation results in long-term remission in multiple relapsed primary CNS lymphoma.
Eur J Haematol
; 101(1): 115-118, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29624748
12.
Neurokinin 1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant.
Future Oncol
; 14(1): 77-92, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-29130344
13.
Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a systematic review and meta-analysis.
Support Care Cancer
; 26(1): 21-32, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28861627
14.
Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.
Support Care Cancer
; 26(11): 3773-3780, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-29808377
15.
Efficacy and Safety of Oral NEPA (Netupitant/Palonosetron), the First Fixed-Combination Antiemetic, in Patients With Gynecological Cancers Receiving Platinum-Based Chemotherapy.
Int J Gynecol Cancer
; 28(6): 1153-1161, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29794499
16.
2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting.
Support Care Cancer
; 25(1): 309-316, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27624464
17.
2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy.
Support Care Cancer
; 25(1): 289-294, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27510316
18.
2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents.
Support Care Cancer
; 25(1): 271-275, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27501965
19.
Bisphosphonates for advanced prostate cancer.
Cochrane Database Syst Rev
; 12: CD006250, 2017 12 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-29278410
20.
Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy.
Cancer
; 122(15): 2418-25, 2016 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27176138